
Heart Failure with Preserved Ejection Fraction (Diastolic CHF) and SGLT-2 Inhibitor Therapy
0:00
11:32
The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF).
Now let us dig a bit more into those headlines.
Otros episodios de "Hospital and Internal Medicine Podcast"



No te pierdas ningún episodio de “Hospital and Internal Medicine Podcast”. Síguelo en la aplicación gratuita de GetPodcast.







